Who are Optiray 320's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Imeron, E-Z-Hd, Visipaque 270, Ultravist 370, Ioxitol, IOPAMIDOL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ioversol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Optiray 320 — Competitive Intelligence Brief

Optiray 320 (IOVERSOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiographic Contrast Agent [EPC]. Area: Hematology.

marketed Radiographic Contrast Agent [EPC] Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Optiray 320 (IOVERSOL) — Liebel-Flarsheim. Optiray 320 works by blocking X-rays, allowing for clearer images during medical imaging procedures.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
Optiray 320 TARGET	IOVERSOL	Liebel-Flarsheim	marketed	Radiographic Contrast Agent [EPC]	1988-01-01
Imeron	IOMEPROL		marketed	Radiographic Contrast Agent [EPC]	2024-01-01
E-Z-Hd	BARIUM SULFATE		marketed	Radiographic Contrast Agent [EPC]	2016-01-01
Visipaque 270	IODIXANOL	GE HealthCare	marketed	Radiographic Contrast Agent	1996-01-01
Ultravist 370	IOPROMIDE	Bayer	marketed	Radiographic Contrast Agent	1995-01-01
Ioxitol	IOXILAN	Guerbet	marketed	Radiographic Contrast Agent	1995-01-01
IOPAMIDOL	IOPAMIDOL		marketed	Radiographic Contrast Agent [EPC]	1985-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiographic Contrast Agent [EPC] class)

· 5 drugs in this class
Deseret Biologicals, Inc. · 1 drug in this class
GE HealthCare · 1 drug in this class
Liebel-Flarsheim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Optiray 320 — Competitive Intelligence Brief. https://druglandscape.com/ci/ioversol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab